posted
MSEP - Real company with real products....do your dd.
Amazing news!!!
MotorSports Emporium Heads for Indy Monday May 22, 9:30 am ET GS610(TM) Brake Fluid Represented in Indianapolis 500
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--May 22, 2006--MotorSports Emporium Inc. (OTCBB:MSEP - News) today announced its high performance brake fluid GS610(TM) will be represented throughout the grid during the Indianapolis 500.
ADVERTISEMENT David Keaveney, MSEP President and CEO comments, "We are heading to the greatest spectacle in racing - the Indianapolis 500. Our brake fluid, GS610(TM), will be used by the five drivers of Andretti Green Racing - Bryan Herta, Dario Franchitti, Tony Kanaan and team owner Michael Andretti along with his son and 19 year old rookie sensation Marco Andretti. Arie Luyendyk Jr. - son of two time Indy 500 winner Arie Luyendyk will also use GS610(TM). A total of thirty-three cars make up the grid for Sunday's 90th running of the Indianapolis 500, six will be using our fluid."
Bryan Herta and Arie Luyendyk will both have the GS610(TM) logo on there race suits and helmet. Additionally, Arie Luyendyk Jr. will have the GS610 (TM) logo on the rear side and front nose of his race car.
posted
Isn't this thread supposed to be started before the market closes? I'm in PGPM hoping for some fun in the morning.
Posts: 192 | Registered: May 2006
| IP: Logged |
posted
MSEP... I'm with Joe... didn't drop today after yesterdays spike, providing nice support at current level... Indy 500 is coming, and MSEP is representin'... it's gonna be awesome...
Adlai_
-------------------- MSEP Posts: 599 | From: Springfield, MO | Registered: Feb 2006
| IP: Logged |
posted
XcelPlus International Announces Shareholder Listen Only Conference Call Saturday May 20, 6:00 am ET
SALUDA, VA--(MARKET WIRE)--May 20, 2006 -- XcelPlus (Other OTC:XLPI.PK - News) is pleased to announce it will hold a listen only conference call on Wednesday, May 24th 2006 at 9 p.m. Eastern time hosted by Bill Smith, CEO of XcelPlus International. The purpose of this call will be to discuss the future direction of the company and help educate shareholders on various topics of interest regarding XcelPlus. "We feel the company is ready to move forward in its plans to emerge as a leader in the E85 market and want to keep our shareholders as well informed as possible," stated Bill Smith, CEO of XcelPlus International. Shareholders will have until the end of business on Tuesday, May 23rd 2006 to email any questions or concerns they may have to Brad Novak in our I.R. department at bnovak*xcelplus.com. The company will attempt to answer as many these questions as time allows for.
ADVERTISEMENT
The dial in number for the call will be 1-866-244-4616. Shareholders may dial in up to 10 minutes before the scheduled conference call begins.
We look forward to speaking to our shareholders and sharing our vision for the future.
About XcelPlus International:
XcelPlus International, Inc. is a specialty chemicals and lubricants company located in Saluda, Virginia.
This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties. Although XcelPlus International believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any assumption could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion should not be regarded as a representation by XcelPlus International Inc. or any other person that the objective and plans of XcelPlus International Inc. will be achieved.
For investor relations you can contact Brad Novak at bnovak*xcelplus.com or by phone at 949-661-5780.
Contact: For investor relations you can contact: Brad Novak Email: bnovak*xcelplus.com Phone: 949-661-5780
Posts: 261 | From: NJ | Registered: May 2005
| IP: Logged |
Rudy 45 Acquires Early Detect Marketing Revenues to be Approximately $35-40 Million
SANTA MONICA, Calif., May 23, 2006 (PRIMEZONE) -- RUDY 45 (Pink Sheets:RDYF) announces that it has entered into a new LOI effective April 30, 2006, to acquire EDI Marketing (EDIM), a wholly owned subsidiary of Early Detect Incorporated (EDI). EDIM will receive an assignment from EDI of all sales and marketing contracts with respect to EDI's integrated line of in-home self-testing healthcare diagnostic products. These contracts are estimated to result in revenues of $35-$40 million dollars.
About EDI Marketing
Headquartered in Costa Mesa, California, Early Detect Incorporated employs 26 people in 4 different locations in Southern California, Phoenix, and Dallas. EDI Marketing distributes their products to some of the most nationally known companies in the U.S. They distribute nationally to CVS Corp (NYSE:CVS) and regionally to Costco Wholesale Corporation (Nasdaq:COST). In addition, they also sell to major chains in Canada. EDI holds all patents on most of their products and either manufactures them directly or uses independent labs.
As an investment company that has elected to be treated as a 'Business Development Company' (BDC) under the Investment Company Act of 1940, Rudy 45 is looking to invest in companies that are cash flow positive or likely to become cash flow positive in the foreseeable future based on sound economic fundamentals. These entities will have the prospect for expansion as a result of access to capital and/or additional management acumen. As part of this strategic process, the Company is looking for investment opportunities in all consumer product categories and/or services that have the potential for a positive return on investment, both in terms of current income and capital appreciation.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," forecasts," potential," or "continue," or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements.
CONTACT: Nassau International Consultants, Inc. (516) 238-4936 nicirkm**********
Higher volume today. Moved onto pinks awaiting proper filings. I look for a short term play on this.
Posts: 271 | From: USA | Registered: Mar 2005
| IP: Logged |
posted
ANDREA ELECTRONICS CORP Quick Quote: ANDR 0.08 (Even)
Samsung Electronics Licenses Audio Technoligies from Andrea Electronics for Use in Q1 Ultra Mobile PC 5/23/2006
BOHEMIA, N.Y., May 23, 2006 (BUSINESS WIRE) -- Andrea Electronics Corporation (OTCBB: ANDR) ("Andrea"), a leading developer of hardware and software microphone technologies, today announced that the company has licensed its patented stereo array microphone and noise reduction audio input software to Samsung Electronics America, Inc. for use in the company's Q1 Ultra Mobile PC.
"We are very pleased to license and imbed our microphone technologies into a new class of computer devices for a company as inventive and highly respected as Samsung," said Douglas J. Andrea, president and chief executive officer of Andrea Electronics. "This agreement demonstrates our dedication to execute on our vision to provide voice input solutions for customers requiring high quality audio for VoIP and speech driven applications."
The array microphone gives Q1 users the ability to make calls over the Internet using VoIP while utilizing a provider's software. The microphone also allows users to employ the voice recognition capabilities of Windows XP Tablet Edition and other Microsoft software.
About Andrea Electronics
Andrea Electronics Corporation designs, develops and manufactures audio technologies and equipment for enhancing applications that require high performance and high quality voice input. The Company's patented Digital Super Directional Array (DSDA(R)), patented PureAudio(R), and patented EchoStop(TM) far-field microphone technologies enhance a wide range of audio products to eliminate background noise and ensure the optimum performance of voice applications. Visit Andrea Electronics' website at www.AndreaElectronics.com or call 1-800-707-5779.
This press release contains certain forward looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties. The Company wishes to caution readers not to place undue reliance on any such forward looking statements, which reflect management's analysis only as the date made. The Company does not undertake any obligation to publicly revise these forward looking statements to reflect events or circumstances that arise after the date of such statements.
SOURCE: Andrea Electronics Corporation
Andrea Electronics Media: Corisa L. Guiffre, 631-719-1800 or 800-707-5779
Medistem Files U.S. Patent Application for Innovative Stem Cell Technology to Treat Lower Back Disorders; Stem Cell Company's Discovery Could Provide Breakthrough for Patients with Lumbar-Related Ailments by Preventing Disc Degeneration Business Wire - May 23, 2006 16:01
SCOTTSDALE, Ariz., May 23, 2006 (BUSINESS WIRE) -- Medistem Laboratories, Inc. (OTCBB:MDSM)(FWB:S2U), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, announced today its filing of a U.S. patent application for an innovative cellular technology to treat lower back ailments by addressing causal issues and developing methodologies to prevent disc degeneration.
Back pain costs the U.S. economy over $50 billion annually and represents the second most common reason for visits to a doctor. It is estimated that 10% of 50-year-old discs and 60% of 70-year-old discs are severely degenerated. The patent application represents a potential therapeutic breakthrough for patients worldwide who suffer from chronic lumbar pain and related lower back disorders caused by disc degeneration. The novel technology is designed to address these problems through the application of regenerative stem cell-based medicine. The proprietary technology increases the potential market value of Medistem's Intellectual Property portfolio.
"The future success of Medistem lies in the commercialization of the best, most innovative and far-reaching stem cell technologies being developed in the world of science," said Neil Riordan, Ph.D., Chairman, and CEO of Medistem. "This latest patent filing is a significant achievement and we're excited by the potential market opportunities and added corporate value presented by our expanding portfolio of intellectual property."
The Medistem discovery relates to the administration of one or more cell types to stimulate lumbar angiogenesis, decrease inflammation, and stimulate regeneration. Significantly, the concept of therapeutic angiogenesis has been investigated for treatments of heart disease, peripheral arterial disease, and other ischemia-related pathologies but only Medistem's technology teaches its groundbreaking potential use for the treatment of lower back ailments associated with disc degeneration. In addition, while a variety of medical approaches exists today to treat lower back problems and associated pain, none actually prevents the process of disc degeneration.
"Common early intervention methods such as exercise, anti-inflammatories and analgesics do not influence the root cause of these problems, while other more serious interventions including spinal fusion, surgery, and artificial disc implants too often present adverse effects, invasiveness and limited full recovery," Riordan added. "We believe we are on our way to developing a major market alternative and superior regenerative solution that would provide safe, effective relief for people worldwide suffering from lumbar-related ailments."
About Medistem Laboratories, Inc.
Medistem Laboratories is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem's corporate mission is to transform these stem cells into valuable medical treatments. The Company intends to create these treatments from adult stem cells derived from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, but not the controversial embryonic or fetal stem cells that are the focus of ethical and moral debates in some communities. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients. Initial development and treatment focus will use proprietary technology and cells sourced from umbilical cords, fat, bone marrow, and muscle for advanced treatment of cerebral palsy, stroke, cardiovascular disease and orthopedic diseases, primarily for the international marketplace. Additional applications ultimately will be targeted to the treatment of neurological disorders such as Parkinson's, Alzheimer's and certain types of cancer. Medistem believes it may hold a substantial competitive edge in the worldwide emerging market for stem cell-sourced medical solutions, positioning it to become a leading global provider of stem cell treatments on a fee-for-service basis, while accumulating intellectual property based on clinical and laboratory findings. For more information, please visit http://www.trilogy-capital.com/tcp/medistem/. To read or download Medistem's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/medistem/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/medistem/quote.html. Medistem is traded on the Frankfurt, Germany, stock exchange under the symbol S2U.
Cautionary Statement
This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements contained herein can be identified by the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates," or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements that are not historical facts, are only predictions. No assurances can be given that the future results indicated, whether expressed or implied, will be achieved.
SOURCE: Medistem Laboratories, Inc.
Medistem Laboratories, Inc. Neil Riordan, Ph.D., 954-727-3662 riordan*medisteminc.com
posted
who cares whats gapping tomorrow, it doesnt mean squat to anyone thats not in, start this thread at about 1 hour before the market closes then it would help. Otherwise it will just encourage people to buy a gap and end up chasing which is a bad idea most of the time.
Never buy a gap unless you really know what you are doing!
Posts: 406 | Registered: Oct 2005
| IP: Logged |
posted
No one is suggesting to buy a gapper and of course you should never buy anything unless you know what you are doing. If you don't like this thread there is a simple solution, don't read it.
Posts: 81 | From: Tigard | Registered: May 2006
| IP: Logged |
posted
News for 'CWMF' - (bellwetherreport.com: The Bellwether Report continues to track the recent developments surrounding Commonwealth American Financial Group, Inc./James Monroe Capital)
May 24, 2006 (M2 PRESSWIRE via COMTEX) -- Commonwealth American Financial Group, Inc./James Monroe Capital (OTCPK:CWFG), is a company that our research team will be tracking over the ensuing weeks. They recently came out with a significant corporate development, causing a market stir. The BWR Research Team will continue to bring its subscribers cutting edge research tools, and second to none customer service.
Commonwealth American Financial Group, Inc./James Monroe Capital Commonwealth has initiated a name change to James Monroe Capital Corporation anticipated change should take place within the next couple of weeks, The new company and its officers have chosen a business model of investing in undervalued real estate and businesses that can be acquired at deep discounts and rehabbed for a significant profit or kept in the company's portfolio generating cash flow and profits for the company and its shareholders.
Dr. Julio Jane, partner/developer, inspected the property, negotiated with the seller, and signed a letter of intent on a deal that will buy a $5.5mm (appraised) 31 acre beachfront property in Punta Uva, Costa Rica, for $1.5 mm. Bradford Funding will finance 98% of the initial loan disbursement of $3mm needed to close and begin construction.
James Monroe Capital will own approximately 43% of the corporation which already owns the land. The entire project is estimated to be valued at $20mm when completed 2 years from now. The closing is scheduled to happen in 90 days to allow time for due diligence.
Dr. Jane, who also has an MBA, will be overseeing the $10mm development project, along with Carr Pechtel, Sr., a Costa Rican land baron with an MBA from Harvard.
Yesterday, the company announced that that it intends to complete the acquisition of Taylor Moffitt, LLC, a real estate investment company. Because of price and ownership, the deal resembles what amounts to a reverse merger.
Taylor Moffitt, LLC, an Iowa company, presently holds title to 10 properties: six 2-bedroom and three 3-bedroom rentals, and joint ownership of a warehouse building. McGovern and Taylor Forrester Moffitt have yet to decide what will be done with the three vacant properties, and the warehouse. Most likely the warehouse will go to Moffitt, since he stores his personal property there. Incidentally, that personal property includes a Rolls-Royce and convertible Hummers which Moffitt and has used as collateral to borrow money on a 1 year balloon loan at 100% interest from a private party, to invest in James Monroe Capital. Vacant houses will not be rented, but will be liquidated for capital that James Monroe Capital will leverage on a pending deal.
Moffitt commented, "We're planning something big that we have yet to unveil. The equity in Taylor Moffitt, LLC will be leveraged as seed money on a large arbitrage deal with 100% financing. I am really committed now. If James Monroe Capital doesn't succeed, I'm going down with it." The acquisition terms of Taylor Moffitt, LLC should be finalized within one week.
Following this announcement, Commonwealth American Financial Group, Inc./James Monroe Capital has traded down 50.00% as this company consistently trades back and forth between $0.0001 and $0.0002, on unbelievable volume of over 510 million shares. The BWR Research Team will continue to track the developments surrounding Commonwealth American Financial Group, Inc./James Monroe Capital and many other exciting companies.
To review research on small cap companies Commonwealth American Financial Group, Inc./James Monroe Capital, as well as many more exciting articles we encourage you to visit www.bellwetherreport.com. You can find these reports under the "Today's Articles" section. No credit Card Needed!!
The Bellwether Report will continue to research all of the markets to bring you exciting opportunities!! If you are interested in receiving more information on these small or large cap opportunities as well as other features of our site, feel free to sign up for a complimentary subscription to the #1 online investment tool www.bellwetherreport.com.
Companies looking to advertise with Bellwether Report should email jlee*bellwetherreport.com with the subject line (Advertising).
Posts: 1086 | Registered: Oct 2005
| IP: Logged |
posted
News for 'PDSC' - (Produce Safety and Security International, Inc., Offers Medic Kleen Disinfectant Against HIV and Associated Viruses Medic Kleen Has Been Proven Effective Against the HIV-1, Hepatitis B and Hepatitis C Viruses and Approved for Use in the United States, Canada and Republic of South Africa)
PRESCOTT, AZ, May 24, 2006 (MARKET WIRE via COMTEX) -- Produce Safety and Security International, Inc. (PINKSHEETS: PDSC), ("PDSC"), a sanitation disinfectant process supplier to the food and medical industries, is pleased to offer Medic Kleen(TM), for use as an effective germicidal disinfectant for clients that work in environments that are exposed to HIV Type 1 (associated with AIDS), Hepatitis B (HBV) and Hepatitis C (HCV) Viruses.
Medic Kleen(TM) is a patented, high-quality, effective blood and organic stain remover and disinfectant for medical and emergency situations that employs powerful, yet non-toxic, enzymes that remove organic materials off of surfaces, medical tools and clothing. Medic Kleen(TM) is a biodegradable solution that contains both the detergent and a formula of enzymes designed to cause lysis of glycoprotien in infectious agents such as HIV, Smallpox and Hepatitis. This product allows for the safe and easy clean up of even the most persistent stains and is the toughest blood & organic stain remover on the market today.
Medic Kleen(TM) is now approved for entire United States, Canada and Republic of South Africa with the following patents:
1. United States Patent, Simpson, No. US 6,420,332 B1,
A Blood and Organic Stain Remover.
2. United States Patent, Simpson, No. 6,753,306 B2,
A Germicidal and Disinfectant Composition.
3. Republic of South Africa Patent Certificate No. 2001/6034
4. Republic of South Africa Patent Application No. 2005/0020
Clarence Karney, CEO of Produce Safety and Security International, Inc., stated, "Due to the increased numbers of individuals potentially harboring these infectious agents, Produce Safety realizes the growing concern among emergency response teams, medical and dental staff, law enforcement personnel and more recently travel and tourist personnel, educators and co-workers over the possibility of coming in contact with a variety of infectious agents, including human immunodeficiency virus (HIV), hepatitis, and, more recently, anthrax and smallpox." Mr. Karney continues by stating, "We will have sufficient inventories of Medic Kleen(TM) ready for delivery to our clients from our Arizona and Kentucky Distribution Centers, in early June."
About Produce Safety & Security International, Inc. (PDSC)
Produce Safety has developed and patented products for extending the shelf life of perishables. The EPA-registered products sanitize and disinfect against food-borne illness pathogens and disease-causing bacteria. PDSC provides a range of options for retail stores, restaurants, cruise ship lines, disaster cleanups and municipal programs. Furthermore, the process incorporates a complete audit trail, an essential component for complying with government regulations in the USA, Canada and Mexico.
Produce Safety's state-of-the-art ozone process has been shown to extend the shelf life and remove food-borne illness bacteria. This process will provide retail produce departments reduced shrinkage, increase the bottom line and provide a fresher product for the consumer. The customer will be assured of a safe food product, by use of this process, which may be used on organic produce to remove the pathogens. This process uses no chemicals thus meeting the requirements of organic certification.
For further product information, joint venture opportunities, distributorship program information, or program applications, please go to Produce Safety's website: www.foodsafeint.com.Posts: 1086 | Registered: Oct 2005
| IP: Logged |
posted
INSQ just got unbeleivable news this morning It should be a fliyer.
Posts: 517 | From: jupiter, florida, usa | Registered: Apr 2004
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
